ARTICLE
23 December 2019

Supreme Court In No Particular Hurry To Weigh In On Rule 9(b) In FCA Cases

AP
Arnold & Porter
Contributor
Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
The Supreme Court recently took a pass on yet another cert. petition asking it to clarify how Rule 9(b)'s particularity requirement applies to False Claims Act claims.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The Supreme Court recently took a pass on yet another cert. petition asking it to clarify how Rule 9(b)'s particularity requirement applies to False Claims Act claims. As we have written, federal circuit courts have adopted different views as to what precisely a relator must plead in order to satisfy Rule 9(b)—in particular (pun intended), whether a relator must identify specific, representative false claims. In nearly each of the past five Terms, the Supreme Court has denied at least one cert. petition raising this issue. The most recent was United States ex rel. Strubbe v. Crawford County Memorial Hospital, in which the Eighth Circuit had affirmed dismissal of an FCA claim for failure to adequately tie alleged fraudulent conduct to billing.

There, the relators were EMTs and paramedics for an Iowa hospital who alleged they were directed to perform certain fraudulent practices for "billing" and "cost reimbursement purposes." Under circuit precedent, relators could satisfy Rule 9(b) by pleading "the particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were submitted" without alleging a specific, representative false claim. Over a sharp dissent, however, the Eighth Circuit in this instance affirmed dismissal because the allegations showed only a "possibility" that false claims actually were submitted.

Relators sought cert. regarding "what specific knowledge a relator must have to be able to properly plead an FCA case when the relator does not have access to the physical bills sent to the government," outlining a potential split in the circuits as to what specificity is required absent allegations of particular false bills. The Supreme Court ordered defendants to respond, seeming to indicate at least some interest in the issues. Defendants argued that no split exists, asserting that any variation in the circuits' applications of Rule 9(b) amounted to mere "semantic differences." The Supreme Court denied cert. on November 25.

Although defendants in Strubbe downplayed the split, the fact remains that at least six circuits have adopted what they characterize as a "more lenient" pleading standard under Rule 9(b) that does not require the details of an actually-submitted false claim. See, e.g., United States ex rel. Prather v Brookdale Senior Living Communities, 838 F.3d 750 (6th Cir. 2016). Other circuits have professed to adopt a "stricter" standard that, at least as a general matter, requires the relator to identify specific claims for payment. See, e.g., United States ex rel. Grant v. United Airlines, 912 F.3d 190 (4th Cir. 2018). Although FCA watchers were hopeful the Supreme Court might finally take up the issue, the Court may have viewed Strubbe as a poor vehicle since the Eighth Circuit is already on the "relaxed" side of the split. In any event, the law on Rule 9(b) in FCA cases likely will remain muddled unless and until the Supreme Court weighs in.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
23 December 2019

Supreme Court In No Particular Hurry To Weigh In On Rule 9(b) In FCA Cases

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More